Prof. Dr. Meral Beksaç

A rare extramedullary presentation of multiple myeloma: Paraspinal muscle involvement revealed by fdg pet/ct,Multipl myelomanın nadir bir ekstramedüller sunumu: Fdg pet/bt ile gösterilen paraspinal kas tutulumu

Turkish Journal of Hematology, 2021

DOI 10.4274/tjh.galenos.2020.2020.0134 PMID 32329985 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Oncology Research and Treatment, 2021

Quelle: ORCID

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation, 2021

DOI 10.1038/s41409-020-01010-1 PMID 32741961 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

Blood Cancer Journal, 2021

DOI 10.1038/s41408-021-00562-9 PMID 34671024 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP

Bone Marrow Transplantation, 2021

Quelle: ORCID

Bone marrow microenvironment interplay and current clinical practice in multiple myeloma: A review of the balkan myeloma study group

Journal of Clinical Medicine, 2021

DOI 10.3390/jcm10173940 PMID 34501388 12 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

Molecular Cancer, 2021

DOI 10.1186/s12943-021-01380-0 PMID 34090465 70 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

The Lancet Haematology, 2021

DOI 10.1016/s2352-3026(21)00278-7 PMID 34756169 50 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood, 2021

DOI 10.1182/blood-2021-152391 Quelle: ORCID

Comparison of Salvage Autologous Hematopoietic Cell Transplantation with Outcomes Following Selinexor Combinations Among Double/Triple Refractory Myeloma Patients

Blood, 2021

DOI 10.1182/blood-2021-148835 4 Zitationen (OpenAlex) Quelle: ORCID

Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.21.01045 PMID 34520219 31 Zitationen (Europe PMC) Quelle: ORCID

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

The Lancet Oncology, 2021

DOI 10.1016/s1470-2045(21)00128-5 PMID 34087126 275 Zitationen (Europe PMC) Quelle: ORCID

Daratumumab-based treatment for immunoglobulin light-chain amyloidosis

New England Journal of Medicine, 2021

DOI 10.1056/nejmoa2028631 PMID 34192431 574 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

The Lancet Oncology, 2021

DOI 10.1016/s1470-2045(20)30680-x PMID 33301738 53 Zitationen (Europe PMC) Quelle: ORCID

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Leukemia and Lymphoma, 2021

DOI 10.1080/10428194.2020.1832672 PMID 33112184 15 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

British Journal of Haematology, 2021

DOI 10.1111/bjh.17338 PMID 33724461 137 Zitationen (Europe PMC) Quelle: ORCID

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

Journal of Hematology and Oncology, 2021

DOI 10.1186/s13045-021-01066-6 PMID 33794982 142 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.8046 1 Zitation (OpenAlex) Quelle: ORCID

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

British Journal of Haematology, 2021

DOI 10.1111/bjh.17321 PMID 33555030 11 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Highlighting the prognostic importance of measurable residual disease among acute myeloid leukemia risk factors,Akut myeloid lösemi risk faktörleri arasında ölçülebilir kalıntı hastalığın prognostik öneminin vurgulanması

Turkish Journal of Hematology, 2021

DOI 10.4274/tjh.galenos.2020.2020.0157 PMID 33112099 Frei zugänglicher VolltextQuelle: ORCID

Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

Clinical Lymphoma, Myeloma and Leukemia, 2021

DOI 10.1016/j.clml.2020.11.017 PMID 33380380 Quelle: ORCID

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Blood, 2021

DOI 10.1182/blood-2021-146907 3 Zitationen (OpenAlex) Quelle: ORCID

Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Blood, 2021

DOI 10.1182/blood-2021-148879 2 Zitationen (OpenAlex) Quelle: ORCID

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation: F. Sahebi et al

Transplantation and Cellular Therapy, 2021

DOI 10.1016/j.jtct.2021.09.008 PMID 34543768 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Blood, 2021

DOI 10.1182/blood-2021-145289 Quelle: ORCID

Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

European Journal of Haematology, 2021

DOI 10.1111/ejh.13602 PMID 33580608 Frei zugänglicher VolltextQuelle: ORCID

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Leukemia, 2021

DOI 10.1038/s41375-020-01016-0 PMID 32814840 103 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Blood, 2021

DOI 10.1182/blood-2021-147108 Quelle: ORCID

Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

Blood, 2021

DOI 10.1182/blood-2021-152444 Quelle: ORCID

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Bone Marrow Transplantation, 2021

DOI 10.1038/s41409-021-01286-x PMID 33976382 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood, 2021

DOI 10.1182/blood-2021-146820 12 Zitationen (OpenAlex) Quelle: ORCID

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Blood, 2021

DOI 10.1182/blood-2021-153694 Quelle: ORCID

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma

Cell Death and Disease, 2021

DOI 10.1038/s41419-021-03510-4 PMID 33627630 22 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

THE ROLE OF UPFRONT AUTOTRANSPLANTATION AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FINAL ANALYSIS OF THE RANDOMIZED PHASE 3 EMN02/HO95 STUDY

Haematologica, 2021

Quelle: ORCID

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Blood, 2021

DOI 10.1182/blood-2021-153905 Quelle: ORCID

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

The Lancet Oncology, 2021

DOI 10.1016/s1470-2045(20)30756-7 PMID 33662288 215 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017

Bone Marrow Transplantation, 2021

Quelle: ORCID

Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

Clinical Lymphoma Myeloma and Leukemia, 2021

Quelle: ORCID

Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM)

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.8017 20 Zitationen (OpenAlex) Quelle: ORCID

P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia, 2021

DOI 10.1016/s2152-2650(21)02318-1 4 Zitationen (OpenAlex) Quelle: OpenAlex

MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

Clinical Lymphoma Myeloma & Leukemia, 2021

DOI 10.1016/s2152-2650(21)01948-0 1 Zitation (OpenAlex) Quelle: OpenAlex

Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

Transplantation and Cellular Therapy, 2021

DOI 10.1016/s2666-6367(21)00516-9 Frei zugänglicher VolltextQuelle: OpenAlex

Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

Transplantation and Cellular Therapy, 2021

DOI 10.1016/s2666-6367(21)00343-2 Frei zugänglicher VolltextQuelle: OpenAlex

NK Hücresel Tedaviler

Turkiye Klinikleri Hematology - Special Topics, 2021

Quelle: OpenAlex

Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience

LLM Dergi, 2021

DOI 10.5578/llm.20219802 Frei zugänglicher VolltextQuelle: OpenAlex